Advertisement

Topics

Vivace Therapeutics Emerges from Stealth to Turn Novel Biology into First-in-Class Cancer Therapies

13:00 EDT 30 Jun 2017 | Drug Discovery Development

Vivace is initially concentrating on inhibitors of the Hippo-YAP signaling pathway.
Contributed Author: 
Vivace Therapeutics
Topics: 

Original Article: Vivace Therapeutics Emerges from Stealth to Turn Novel Biology into First-in-Class Cancer Therapies

NEXT ARTICLE

More From BioPortfolio on "Vivace Therapeutics Emerges from Stealth to Turn Novel Biology into First-in-Class Cancer Therapies"

Advertisement
Quick Search
Advertisement
Advertisement